JPMorgan Chase & Co. Analysts Give AstraZeneca (LON:AZN) a GBX 7,900 Price Target
JPMorgan Chase & Co. set a GBX 7,900 ($103.23) target price on AstraZeneca (LON:AZN) in a research report report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other research reports. Jefferies Financial Group decreased their target price on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a hold rating for the company in a research report on Friday, May 24th. Citigroup reissued a buy rating and issued a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research report on Monday, May 13th. Barclays set a GBX 7,600 ($99.31) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday, August 9th. Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Finally, UBS Group reaffirmed a sell rating and set a GBX 5,700 ($74.48) price objective (up previously from GBX 5,400 ($70.56)) on shares of AstraZeneca in a research report on Wednesday. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of GBX 6,688.24 ($87.39).
Shares of LON:AZN opened at GBX 7,256 ($94.81) on Thursday. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,475.15 ($97.68). The firm has a market capitalization of $95.19 billion and a P/E ratio of 42.38. The stock has a 50 day moving average price of GBX 6,772.74 and a 200-day moving average price of GBX 6,232.71. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Operating Income
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.